Sano Women's Health is pioneering antifungal innovation with its flagship product to treat recurrent vulvovaginal candidiasis (RVVC) using Occidiofungin - The Fungus Killer™. The first part of Phase 1 FDA human trials to treat recurrent vulvovaginal candidiasis (RVVC) has been successfully completed. Sano Women's Health is working to bring this innovative treatment to market, pending successful clinical trials and regulatory approval. RVVC is associated with chronic and recurrent yeast infections affecting up to 9 million women in the U.S. per year. FDA has granted Sano Women's Health qualified infectious disease product (QIDP) designation for its RVVC drug, which extends the expiration date on Occidiofungin patents for five years. Sano women's Health believes it's poised to address a multi-billion U.S. market for treating recurrent and drug-resistant vaginal yeast infections.
Sano Women’s Health is a clinical-stage biotechnology company focused on developing novel therapeutics for women’s health conditions with significant unmet medical need. Our pipeline includes programs targeting recurrent vulvovaginal candidiasis (RVVC), postpartum mastitis and breast abscesses, and breast cancer. Led by our clinical-stage antifungal therapeutic OCF001, we are advancing first-in-class approaches designed to address infections and diseases where current treatment options remain limited or inadequate.
Supporting our pipeline is the proprietary HOAM (Higher-Order Actin Modulating) Discovery Platform, which is being leveraged to develop next-generation therapeutics for oncology and other serious diseases. Through innovative actin-modulating science, Sano Women’s Health is committed to advancing therapies that have the potential to improve outcomes for millions of patients.
Sano Women's Health
Our Mission
At Sano Women’s Health, we believe innovative science can redefine treatment options for diseases that continue to lack effective therapies. We are committed to advancing innovative therapeutics for women’s health conditions that have long lacked meaningful innovation, including recurrent fungal infections, postpartum diseases, and cancer. Through our clinical and preclinical pipeline, we are developing first-in-class therapies and platforms designed to address significant unmet medical needs and improve patient outcomes and quality of life.
Our Story
Sano Chemicals Inc., DBA Sano Women’s Health, was founded in 2012 in Bryan, Texas, alongside the innovative research environment of Texas A&M University. Since its founding, the company has focused on translating breakthrough scientific discoveries into novel therapeutics for women’s health and oncology. Through a combination of scientific innovation, entrepreneurial leadership, and strategic development, Sano has been recognized through programs including the Texas New Venture Competition and MassChallenge, building a reputation for innovation, integrity, and advancing therapies for areas of significant unmet medical need.
